Wesper Journal
Subclinical sleep apnea represents the often-overlooked middle ground between benign snoring and clinically diagnosed obstructive sleep apnea (OSA). Though these patients may not meet the standard AHI ≥ 5 threshold, they frequently experience measurable physiological disruptions — including flow-limited breathing, mild oxygen desaturations, and fragmented sleep. These subtle patterns contribute to increased cardiovascular strain, metabolic dysregulation, and cognitive impairment long before overt disease appears. Traditional single-night polysomnography often misses these early deviations, leaving at-risk patients undiagnosed until symptoms or comorbidities worsen.
Advancements in medical-grade home sleep testing (HSAT) are changing that trajectory. By capturing true respiratory effort, oxygenation, and positional data across multiple nights in the patient’s natural environment, systems like Wesper’s allow clinicians to detect the earliest signs of airway instability and hypoxic burden. This longitudinal insight enables proactive intervention — through lifestyle changes, airway optimization, or targeted therapy — before OSA becomes entrenched. As Dr. Chelsie Rohrscheib, PhD, notes, medical-grade HSAT redefines the future of sleep medicine by shifting care from reactive diagnosis to preventive precision.
Continue reading
Sleep apnea in your 20s, characterized by symptoms like loud snoring, excessive fatigue, and difficulty concentrating, can significantly disrupt daily life and health. Early diagnosis and exploring treatment options such as CPAP, oral appliances, and lifestyle changes, alongside leveraging healthcare...
Continue reading
GLP-1 Receptor Agonists and Obstructive Sleep Apnea (OSA): A New Era in Sleep Health ManagementThe approval of GLP-1 receptor agonists, such as Zepbound (tirzepatide), represents a groundbreaking development in the treatment of Obstructive Sleep Apnea (OSA). These medications not only...
Continue reading
In a landmark move, the FDA approved Zepbound (tirzepatide), the first GLP-1-based medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, offering hope beyond traditional CPAP therapy. It works by activating GLP-1 and GIP hormone...
Continue reading
Many people experience immediate mental clarity and reduced brain fog after just one night of using CPAP therapy, as it alleviates airway obstruction and enhances sleep quality. The therapy delivers consistent airway support, leading to improved oxygen levels and restorative...
Continue reading
provider portal